4-tert.Butylamino-butanol-(1) | 118768-38-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-tert.Butylamino-butanol-(1)
• 英文别名: 4-(Tert-butylamino)-1-butanol；4-(tert-butylamino)butan-1-ol
• CAS: 118768-38-0
• 化学式: C₈H₁₉NO
• 分子量: 145.245
• InChiKey: NJHLILWJNXPORW-UHFFFAOYSA-N

物化性质

• 沸点：
  41-42 °C
• 密度：
  0.869±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-tert.Butylamino-butanol-(1) 在 盐酸 、 sodium nitrite 作用下， 生成 N-tert-butyl-N-(4-hydroxybutyl)nitrosamine
  参考文献：
  名称：

  Syntheses of N-alkyl-N-(hydroxy- or oxo-alkyl)nitrosamines related to N-butyl-N-(4-hydroxybutyl)nitroamine, a potent bladder carcinogen.

  摘要：

  为研究其在大鼠体内的致癌效应，合成了19种与N-丁基-N-(4-羟基丁基)亚硝胺（一种强效膀胱致癌物）结构相关的N-烷基-N-(羟基或氧代烷基)亚硝胺。这些亚硝胺包括N-烷基-N-(4-羟基丁基)亚硝胺、N-烷基-N-(3-羟基丙基)亚硝胺、N-烷基-N-(2-羟基烷基)亚硝胺以及N-烷基-N-(2-或3-氧代烷基)亚硝胺。它们主要通过相应N-烷基-N-(羟基烷基)胺的亚硝化反应制备。含有氧代基团的亚硝胺则通过铬酐氧化相应的具有次级羟基的N-烷基-N-(羟基烷基)亚硝胺制备。

  DOI：

  10.1248/cpb.26.3891
• 作为产物：
  描述：

  N-叔丁基-琥珀酰胺酸 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 4-tert.Butylamino-butanol-(1)
  参考文献：
  名称：

  The Lithium Aluminum Hydride Reduction of Some N-Substituted Succinimides¹

  摘要：

  DOI：

  10.1021/jo01065a012

文献信息

• Borane-Methyl Sulfide Reductive Cyclization of ω-Ester Alkylamides: A Convenient Synthesis of<i>N</i>-Substituted Cyclic Amines
  作者：Michael C. Venuti、Oswald Ort

  DOI：10.1055/s-1988-27777

  日期：——

  Borane-methyl sulfide (BMS) reduction of variously N-substituted succinamic and glutaramic esters affords the corresponding N-substituted pyrrolidines and piperidines in high yields. The limitations, mainly caused by steric hinderance around the amine nitrogen, and putative intermediates involved in this conversion, as detected by incomplete reaction and/or synthesis followed by BMS reduction, indicate that cyclization and amide reduction successfully compete with ester reduction to afford the N-substituted cyclized amines.

  硼烷-硫化甲基（BMS）还原各种N-取代的琥珀酰胺和戊二酰胺酯，可以高产率地得到相应的N-取代吡咯烷和哌啶。这一转化过程中，由于胺氮周围的空间阻碍限制，以及通过不完全反应和/或合成后续的BMS还原检测到的假定中间体，表明环化作用和酰胺还原成功地与酯还原竞争，从而得到了N-取代的环化胺。
• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES
  申请人：Arvinas, Inc.

  公开号：US20190151295A1

  公开（公告）日：2019-05-23

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4); the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hppel-Lindau, cereblon, ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为白细胞介素-1受体相关激酶4（IRAK-4；目标蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合E3泛素连接酶的Von Hppel-Lindau、cereblon配体的双功能化合物，另一端结合目标蛋白的部分，使得目标蛋白靠近泛素连接酶以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由目标蛋白聚集或积累导致的疾病或紊乱。
• CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
  申请人：LEHMANN-LINTZ Thorsten

  公开号：US20110217311A1

  公开（公告）日：2011-09-08

  The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2 a or Mnk2 b ) and/or variants thereof.

  本发明涉及新型噻吩并嘧啶化合物，其一般公式，包含这些化合物的药物组合物，以及它们在预防和/或治疗可通过抑制Mnk1和/或Mnk2（Mnk2a或Mnk2b）及其变体的激酶活性而影响的疾病中的治疗用途。
• THIAZOLE COMPOUND AND USE THEREOF
  申请人：Otsuka Pharmaceutical Company, Limited

  公开号：EP1748044A1

  公开（公告）日：2007-01-31

  An object of the present invention is to provide a novel thiazole compound with specific inhibitory activity against phosphodiesterase 4. The present invention provides a compound represented by Formula (1), an optical isomer thereof, or a salt thereof: wherein R1 is a di-C1-6 alkoxyphenyl group; R2 is any one of the following groups (a) to (t): (a) a phenyl group; (b) a naphthyl group; (c) a pyridyl group; (d) a furyl group; (e) a thienyl group; (f) an isoxazolyl group; (g) a thiazolyl group; (h) a pyrrolyl group; (i) an imidazolyl group; (j) a tetrazolyl group; (k) a pyrazinyl group; (1) a thienothienyl group; (m) a benzothienyl group; (n) an indolyl group; (o) a benzimidazolyl group; (p) an indazolyl group; (q) a quinolyl group; (r) a 1,2,3,4-tetrahydroquinolyl group; (s) a quinoxalinyl group; and (t) a 1,3-benzodioxolyl group; and A is any one of the following groups (i) to (vi): (i) -CO-B- wherein B is a C1-6 alkylene group; (ii) -CO-Ba wherein Ba is a C2-6 alkenylene group; (iii) -CH(OH)-B-; (iv) -COCH(COOR3)-Bb- wherein R3 is a C1-6 alkyl group and Bb is a C1-6 alkylene group; and (v) -Bc- wherein Bc is a C2-6 alkylene group.

  本发明的目的是提供一种对磷酸二酯酶4具有特异抑制活性的新型噻唑化合物。本发明提供一种由式（1）表示的化合物，其光学异构体或盐：其中R1是二C1-6烷氧基苯基基团；R2是以下分组之一（a）至（t）中的任意一种：（a）苯基；（b）萘基；（c）吡啶基；（d）呋喃基；（e）噻吩基；（f）异氧唑基；（g）噻唑基；（h）吡咯基；（i）咪唑基；（j）四唑基；（k）吡嗪基；（l）噻吩噻吩基；（m）苯并噻吩基；（n）吲哚基；（o）苯并咪唑基；（p）吲哚基；（q）喹啉基；（r）1,2,3,4-四氢喹啉基；（s）喹啉基；和（t）1,3-苯并二氧杂环戊基；以及A是以下分组之一（i）至（vi）中的任意一种：（i）-CO-B-，其中B是C1-6烷基基团；（ii）-CO-Ba，其中Ba是C2-6烯基基团；（iii）-CH(OH)-B-；（iv）-COCH(COOR3)-Bb-，其中R3是C1-6烷基基团，Bb是C1-6烷基基团；和（v）-Bc-，其中Bc是C2-6烷基基团。
• Hindered Amine Nitric Oxide Donating Polymers for Coating Medical Devices
  申请人：Cheng Peiwen

  公开号：US20070264225A1

  公开（公告）日：2007-11-15

  Disclosed are hindered amine nitric oxide (NO) donating polymers for coating implantable medical devices. The polymers include sterically hindered secondary amines that do not react with monomer carbonyls or electrophilic alkenes, facilitating the synthesis of the NO donating polymers. The polymers are coated on implantable medical devices, providing anti-restenosis therapy by the release of NO at the implantation site.

  本发明涉及一种用于涂覆植入式医疗器械的受阻胺硝酸氧化物（NO）捐赠聚合物。该聚合物包括具有立体位阻的次级胺，不与单体羰基或亲电性烯烃反应，从而便于合成NO捐赠聚合物。该聚合物被涂覆在植入式医疗器械上，在植入部位释放NO，提供抗再狭窄治疗。